ASSESSMENT OF PROTEINURIA REPORTED AS ADVERSE EVENTS IN DE NOVO RENAL TRANSPLANT RECIPIENTS RECEIVING AN EVEROLIMUS-BASED REGIMEN: 24-MONTH RESULTS FROM TRANSFORM

被引：0
|
作者：
Legendre, C. [5 ]
Buchler, M. [7 ]
Pernin, V. [4 ]
Berger, S. P. [13 ]
Oppenheimer, F. [11 ]
Wiseman, A. [14 ]
Viklicky, O. [3 ]
Russ, G. R. [1 ]
Danguilan, R. [10 ]
Basic-Jukic, N. [2 ]
Mor, E. [9 ]
Narvekar, P. [12 ]
Hernandez-Gutierrez, M. P. [12 ]
Bernhardt, P. [12 ]
Gharbi, H. [6 ]
Sommerer, C. [8 ]
机构：
[1] Royal Adelaide Hosp, Cent & Northern Adelaide Renal & Transplantat Ser, Adelaide, SA, Australia
[2] Univ Hop Ctr Zagreb, Zagreb, Croatia
[3] Inst Clin & Expt Med, Dept Nephrol, Transplant Ctr, Prague, Czech Republic
[4] CHU Montpellier, Montpellier, France
[5] Hop Necker Enfants Malad, Paris, France
[6] Novartis Pharma SAS, Rueil Malmaison, France
[7] CHU Tours, Tours, France
[8] Univ Hosp Heidelberg, Dept Nephrol, Heidelberg, Germany
[9] Sheba Med Ctr, Ramat Gan, Israel
[10] Natl Kidney & Transplant Inst, Quezon City, Philippines
[11] Hosp Clin Barcelona, Dept Nephrol & Renal Transplantat, Barcelona, Spain
[12] Novartis Pharma AG, Basel, Switzerland
[13] Univ Med Ctr Groningen, Dept Nephrol, Groningen, Netherlands
[14] Univ Colorado, Sch Med, Aurora, CO USA
来源：
TRANSPLANT INTERNATIONAL | 2020年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
O2
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [1] Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM.
    Legendre, C.
    Berger, S.
    Oppenheimer, F.
    Wiseman, A.
    Steinberg, S.
    Viklicky, O.
    Russ, G.
    Danguilan, R.
    Basic-Jukic, N.
    Mor, E.
    Narvekar, P.
    Gutierrez, M. P. Hernandez
    Bernhardt, P.
    Sommerer, C.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 693 - 694
  • [2] EFFICACY AND SAFETY OF EVEROLIMUS-BASED REGIMEN IN RENAL TRANSPLANT RECIPIENTS WITH DELAYED GRAFT FUNCTION: 24-MONTH RESULTS FROM THE TRANSFORM STUDY
    Citterio, Franco
    Sommerer, Claudia
    Oppenheimer, Federico
    Berger, Stefan
    Viklicky, Ondrej
    Danguilan, Romina
    Basic-Jukic, Nikolina
    Hernandez, Maria-Pilar
    Narvekar, Prachiti
    Bernhardt, Peter
    Legendre, Christophe
    [J]. TRANSPLANT INTERNATIONAL, 2019, 32 : 80 - 80
  • [3] EFFECT OF TACROLIMUS EXPOSURE ON EVEROLIMUS-BASED IMMUNOSUPPRESSION IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: A 24-MONTH ANALYSIS FROM TRANSFORM STUDY
    Citterio, Franco
    Peddi, V. Ram
    Qazi, Yasir
    Kim, Dean
    Vincenti, Flavio
    Berger, Stefan
    Sommerer, Claudia
    Gawai, Apurva
    Hernandez-Gutierrez, Maria-Pilar
    Bernhardt, Peter
    Oberbauer, Rainer
    [J]. TRANSPLANT INTERNATIONAL, 2021, 34 : 254 - 255
  • [4] Antirejection Efficacy in De Novo Renal Transplant Recipients Receiving Everolimus with a Reduced-Exposure Calcineurin Inhibitor-Based Regimen: 24-Month Results from the TRANSFORM Study.
    Silva, H. Tedesco
    Citterio, F.
    Henry, M.
    Srinivas, T. R.
    Watarai, Y.
    Steinberg, S.
    Basic-Jukic, N.
    Garcia, V. D.
    Mor, E.
    Peddi, V. R.
    Narvekar, P.
    Gutierrez, M. P. Hernandez
    Bernhardt, P.
    Pascual, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 358 - 359
  • [5] EVEROLIMUS-BASED IMMUNOSUPPRESSION IN HCV POSITIVE DE NOVO LIVER TRANSPLANT RECIPIENTS: 24-MONTH RESULTS OF A RANDOMIZED CONTROLLED TRIAL
    Saliba, F.
    Metselaar, H. J.
    Beckebaum, S.
    Duvoux, C.
    Navasa, M.
    Dong, G.
    Lopez, P.
    Nevens, F.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S79 - S80
  • [6] De Novo Everolimus-Based Therapy in Renal Transplant Recipients: Effect on Proteinuria and Renal Prognosis
    Loriga, G.
    Ciccarese, M.
    Pala, P. G.
    Satta, R. P.
    Fanelli, V.
    Manca, M. L.
    Serra, G.
    Dessole, P.
    Cossu, M.
    [J]. TRANSPLANTATION PROCEEDINGS, 2010, 42 (04) : 1297 - 1302
  • [7] EFFECT OF DONOR AGE ON EFFICACY AND SAFETY OF DE NOVO RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-EXPOSURE CALCINEURIN INHIBITOR REGIMEN: 24-MONTH RESULTS FROM THE TRANSFORM STUDY
    Pascual, Julio
    Legendre, Christophe
    Vincenti, Flavio
    Tedesco, Helio
    Witzke, Oliver
    Viklicky, Ondrej
    Cruzado, Josep M.
    Hernandez, Maria-Pilar
    Narvekar, Prachiti
    Bernhardt, Peter
    Kuypers, Dirk
    [J]. TRANSPLANT INTERNATIONAL, 2019, 32 : 79 - 79
  • [8] EFFECT OF INDUCTION THERAPY ON OUTCOMES OF DE NOVO RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-DOSE CALCINEURIN INHIBITOR: 24-MONTH RESULTS FROM TRANSFORM STUDY
    Pernin, V.
    Legendre, C.
    Buchler, M.
    Oberbauer, R.
    Vincenti, F.
    Viklicky, O.
    Huynh-Do, U.
    Kim, D.
    Narvekar, P.
    Hernandez-Gutierrez, M. P.
    Bernhardt, P.
    Gharbi, H.
    Kuypers, D.
    [J]. TRANSPLANT INTERNATIONAL, 2020, 33 : 12 - 12
  • [9] Efficacy and Safety Outcomes by Donor Type in De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from Transform
    Berger, S.
    Bakr, M.
    Bemelman, F.
    Danguilan, R.
    De Fijter, H.
    Han, D.
    Kim, M.
    Mor, E.
    Patel, A.
    Gutierrez, M. Hernandez
    Gawai, A.
    Watarai, Y.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 942 - 943
  • [10] LIPID ABNORMALITIES AND CARDIOVASCULAR EVENTS IN RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-EXPOSURE CALCINEURIN INHIBITOR REGIMEN: 24-MONTH ANALYSIS FROM TRANSFORM STUDY
    Sommerer, Claudia
    Legendre, Christophe
    Citterio, Franco
    Watarai, Yoshihiko
    Oberbauer, Rainer
    Basic-Jukic, Nikolina
    Garcia, Valter Duro
    Peddi, V. Ram
    Hernandez-Gutierrez, Maria-Pilar
    Narvekar, Prachiti
    Bernhardt, Peter
    Chadban, Steve
    [J]. TRANSPLANT INTERNATIONAL, 2019, 32 : 71 - 71
12345